Form 6-K BELLUS Health Inc. For: Dec 13
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/16/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- SanDisk upgraded at JPMorgan after investor day; shares climb
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Cowen Sets $15 PT on BELLUS Health Inc. (BLU)
December 13, 2021 10:39 AM ESTCowen analyst Ritu Baral reiterated an Outperform rating and set a $15.00 price target on BELLUS Health Inc. (NASDAQ: BLU) after the company's Ph2 SOOTHE trial of '5937 for rCC met stat sig on its primary endpoint of PBO-adjusted 24-hour cough reduction, with a... More
BELLUS Health Inc. (BLU:CN) (BLU) PT Raised to Cdn$16 at Bloom Burton & Co.
December 13, 2021 10:36 AM ESTBloom Burton & Co. analyst David Martin raised the price target on BELLUS Health Inc. (BLU:CN) (NASDAQ: BLU) to Cdn$16.00 (from Cdn$7.50) while maintaining a Buy (1) rating.
"Since 34% exceeds 23% substantially, we are increasing our target price to $16.00 based on 40% expected peak market share (previously... More
BELLUS Health Inc. (BLU) PT Raised to $18 at BTIG; 'Best-case Scenario Reached'
December 13, 2021 10:25 AM ESTBTIG analyst Justin Zelin raised the price target on BELLUS Health Inc. (NASDAQ: BLU) to $18.00 (from $13.00) while maintaining a Buy rating.
The analyst commented, "This morning, Bellus announced topline data evaluating P2X3 antagonist BLU-5937 in the Phase 2b SOOTHE trial (for RCC) and Phase 2 BLUEPRINT trial (for AD-related pruritus), highlighting an impressive 34.4% (p = 0.003) pbo-adjusted 24h cough frequency reduction at 50mg with an taste AE rate of 6.5%, and a 34.2% (p=0.005) pbo-adjusted change at 200mg with a taste AE rate of 4.8%, clearly differentiating... More
